JWH-200, also known as WIN 55,225, is a member of the aminoalkylindole family, functioning as an analgesic compound with cannabinoid receptor agonist properties. This chemical exhibits a binding affinity, denoted as Ki, of 42 nM at the CB1 receptor, a level of relationship similar to that of THC. Notably, in vivo studies revealed that JWH-200’s analgesic effectiveness exceeded that of other analogs with stronger CB1 binding affinity in vitro, surpassing THC’s analgesic potency by approximately threefold. Interestingly, it achieves this heightened efficacy with a reduced sedative effect, likely attributed to favorable pharmacokinetic characteristics. JWH-200’s discovery dates back to 1991, credited to Sterling Drug, which emerged as a promising candidate for analgesic purposes, following earlier findings related to compounds like pravadoline and WIN 55,212-2.
|CompTox Dashboard (EPA)||DTXSID60145946|
|Chemical and physical data|
|Molar mass||384.479 g·mol−1|
JWH-200 is categorized as a Schedule 9 prohibited substance in Australia, as per the Poisons Standard (October 2015). Under Schedule 9, substances are considered susceptible to abuse or misuse, thus necessitating legal prohibition for manufacture, possession, sale, or use. Exceptions may apply for medical or scientific research, as well as for analytical, teaching, or training purposes, subject to approval by Commonwealth and State or Territory Health Authorities.
In July 2015, JWH-200 was designated as a controlled substance in Canada.
JWH-200’s regulatory status in the United States changed. It was temporarily classified as a Schedule I controlled substance by the US DEA on March 1, 2011, as detailed in 76 FR 11075. This temporary scheduling was made permanent through Section 1152 of the Food and Drug Administration Safety and Innovation Act on July 9, 2012. This designation places JWH-200 in the category of substances considered illegal under federal law.
1. What is JWH-200 (WIN 55,225)?
JWH-200, also known as WIN 55,225, is a chemical compound belonging to the aminoalkylindole family. It serves as an analgesic and functions as a cannabinoid receptor agonist.
2. How does JWH-200 interact with cannabinoid receptors?
JWH-200 acts as a cannabinoid receptor agonist, binding to cannabinoid receptors in the body. It exhibits a binding affinity (Ki) of 42 nM at the CB1 receptor, a level similar to THC.
3. What is JWH-200’s analgesic potency?
In vivo studies, JWH-200 displayed a higher analgesic potency than other analogs with stronger CB1 binding affinity in vitro. Its analgesic effectiveness is approximately three times that of THC while causing fewer sedative effects.
4. Who discovered JWH-200 and when?
JWH-200 was discovered in 1991 by Sterling Drug. Its development as a potential analgesic followed earlier identifications of related compounds like pravadoline and WIN 55,212-2.
5. Is JWH-200 legal in Australia?
No, JWH-200 is classified as a Schedule 9 prohibited substance in Australia under the Poisons Standard. This designation prohibits its manufacture, possession, sale, or use except for approved medical or scientific research, analytical, teaching, or training purposes.
6. What is JWH-200’s status in Canada?
JWH-200 was designated as a controlled substance in Canada in July 2015.
7. How is JWH-200 regulated in the United States?
In the United States, the Drug Enforcement Administration (DEA) temporarily classified JWH-200 as a Schedule I controlled substance on March 1, 2011. This temporary scheduling was made permanent through the Food and Drug Administration Safety and Innovation Act on July 9, 2012, placing it in the category of illegal substances under federal law.
8. What are the potential effects and risks associated with JWH-200?
JWH-200, as a synthetic cannabinoid, may produce effects similar to natural cannabinoids, such as altered mood and perception. However, its use is discouraged due to unpredictable and potentially harmful side effects. It is essential to adhere to local laws and regulations regarding controlled substances and prioritize safety and well-being.
- Exploring Novel Cannabimimetic Derivatives (August 1997): Dutta AK, Ryan W, Thomas BF, Singer M, Compton DR, Martin BR, and Razdan RK delved into the synthesis, pharmacology, and molecular modeling of innovative 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs) in a study from August 1997. This research contributes to the understanding of compounds designed to mimic the effects of cannabinoids.
- Advancements in Cannabimimetic Medicinal Chemistry (2005): Huffman JW and Padgett LW explored recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles, and indenes in a publication from 2005. This study shed light on the evolving landscape of compounds designed to mimic the effects of cannabinoids.
- Antinociceptive (Aminoalkyl)indoles (March 1991): Bell MR, D’Ambra TE, Kumar V, Eissenstat MA, Herrmann JL, Wetzel JR, et al. conducted research in March 1991 focusing on antinociceptive (aminoalkyl)indoles. This study contributes to our understanding of compounds with potential analgesic properties.
- Cannabimimetic Aminoalkylindole Analogues (December 1992): Compton DR, Gold LH, Ward SJ, Balster RL, and Martin BR explored aminoalkylindole analogs with cannabimimetic activity in a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. This research dates back to December 1992.
- Regulatory Framework in Australia (October 2015): The Poisons Standard, in its October 2015 edition, plays a crucial role in regulating substances, including JWH-200, in Australia. This standard classifies and controls substances based on their potential for misuse or abuse.
- Control of JWH-200 in Canada (July 2015): In July 2015, the Government of Canada implemented an order amending Schedule II to the Controlled Drugs and Substances Act, specifically addressing synthetic cannabinoids, including JWH-200.
- Scheduling in the United States (March 2014): The United States Drug Enforcement Administration (DEA) temporarily placed four synthetic cannabinoids, including JWH-200, into Schedule I, a classification that designates them as controlled substances with high potential for abuse. This placement was made temporary, reflecting the ongoing regulatory evaluation of these substances.